Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.

Aida Albadawy,Mohammed Alqudaimi,Hanyue Cui,Xianghui Yan,Jing Sun,Ping Shi
DOI: https://doi.org/10.61186/ibj.4068
2024-01-01
Iranian Biomedical Journal
Abstract:Background : The HSD17B family has been implicated in the prognosis and treatment prediction of various malignancies; however, its association with BLCA remains unclear. This study aimed to evaluate the potential of HSD1781 , as a prognostic biomarker, for the survival of patients with BLCA and to determine its effectiveness as a supplemental biomarker for BLCA. Methods: A series of bioinformatics techniques were applied to investigate the expression of HSD1781 in different types of cancer and its potential association with the prognosis of BLCA patients using diverse databases. The UALCAN, Human Protein Atlas, cBioPortal, Metascape, GEPIA, MethSurv, and TIMER were employed to analyze expression differences, mutation status, enrichment analysis, overall survival, methylation, and immuneinfiltrating cells. The qRT-PCR was implemented to detect the mRNA expression levels of HSD1781 in vitro. Results: Elevated mRNA and protein levels of HSD1781 , surpassing normal levels, were observed in BLCA samples. In addition, the BLCA patients with higher mRNA expression level of HSD1781 significantly reduced the OS. Also, several immune infiltrating cells, including mast cell resting CIBERSORT-ABS, have been identified as tumor-associated biomarker genes, with the potential to significantly influence the immunological environment. Finally, qRT-PCR analysis revealed a significant upregulation of HSD1781 mRNA expression level in the cancer cells compared to the human 293T cells, which was consistent with the bioinformatics data. Conclusion : There is a strong correlation between the elevated HSD1781 expression and positive prognosis in patients with BLCA. Therefore, HSD1781 can be used as a prognostic biomarker in these patients.
What problem does this paper attempt to address?